You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....
MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...
First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...
Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...
DEERFIELD, IL, October 14, 2008 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched...
Follow U.S. news
